NAPSR news: Boehringer Receives First Breakthrough Therapy Designation for the treatment of IPF

Boehringer Ingelheim Pharmaceuticals is the largest U.S. subsidiary of Boehringer Ingelheim Corporation and a member of the Boehringer Ingelheim group of companies.
Spread the Word
Listed Under

* Pharmaceutical Sales
* Cnpr Certification
* Napsrx
* Sales Marketing

* Biotech
* Health

* Washington - District of Columbia - US

WASHINGTON - July 18, 2014 - PRLog -- Boehringer Ingelheim has received the first FDA Breakthrough Therapy designation for the treatment of idiopathic pulmonary fibrosis (IPF). The investigational therapy, Nintedanib is a molecule tyrosine kinase inhibitor (TKI) targeting growth factor receptor. Boehringer has stated that Nintedanib* has the probable outcome of reducing disease progression in IPF by slowing the decline of lung function up to 50%.  The therapy is also in clinical development to become a cancer treatment option for non-small cell lung cancer, ovarian cancer, colorectal cancer and hepatocellular carcinoma.

“We’re excited nintedanib* has been granted breakthrough therapy designation in the US, which we hope will make the treatment available to IPF patients as quickly as possible. Currently there are no FDA-approved treatments available for IPF. We are committed to working with all regulatory bodies to make nintedanib* available to people living with this serious and life-threatening lung disease.” said Professor Klaus Dugi, Chief Medical Officer, Boehringer Ingelheim.

Established in 2012, the Breakthrough Therapy Designation is intended to accelerate the research and development process for drugs designed to treat serious or life threatening conditions. The Breakthrough Therapy Designation was assigned due to significant clinical evidence obtained  by the results from two global Phase III studies (INPULSIS™-1 and INPULSIS™-2) evaluating the efficacy and safety of nintedanib* for the treatment of IPF. The results were also presented at the American Thoracic Society (ATS) International Conference and published in the New England Journal of Medicine in May 2014.

IPF (idiopathic pulmonary fibrosis) is a serious and fatal lung disease that causes permanent scarring of the lungs. The formation of scar tissue is medically referred to as fibrosis. IPF affects as many as 14-43 people per 100,000 worldwide. There is no known cure.

The continuous research and development of this therapeutic breakthrough for this debilitating disease will certainly be life-changing for patients affected.  If successful, Nintedanib will join other effective therapies currently on the market. This will without a doubt bolster the need for both certified and qualified individuals to promote the company’s diversified product portfolio. When industry leaders look for new candidates for sales/marketing positions, they look toward individuals that are industry trained. Companies are looking for people that have the background to sell their product both proficiently and efficiently.

The CNPR is a federally trademarked certification you can earn by demonstrating the necessary knowledge in pharmacology, medical terminology, physiology, and regulations for selling pharmaceuticals. The CNPR examination is dedicated to increasing the professional level of NAPSR members and to developing meaningful and ethical standards fully accepted by both its members and members of the pharmaceutical community.

The CNPR® Program represents a level of industry achievement and a demonstrated knowledge of pharmacology, medical terminology, pharmaceutical selling guidelines, physician selling techniques and industry standards. Pharmaceutical sales candidates who have this training will differentiate themselves from other individuals looking for open positions. Upon successful completion of the training each student will receive the Certification Mark of the CNPR®. CNPR® graduates should immediately utilize the NAPSRx® Career Center to apply for pharmaceutical sales positions.

Individuals that are interested in becoming a Certified National Pharmaceutical Representative (CNPR) can contact the National Association of Pharmaceutical Sales Representatives(NAPSRx) for more information.

Email:*** Email Verified
Tags:Pharmaceutical Sales, Cnpr Certification, Napsrx, Sales Marketing
Industry:Biotech, Health
Location:Washington - District of Columbia - United States
Account Email Address Verified     Account Phone Number Verified     Disclaimer     Report Abuse
Daily News
Weekly News

Like PRLog?
Click to Share